What are the best treatments for Hereditary Angioedema?

The best treatments for Hereditary Angioedema (HAE) focus on managing acute attacks through plasma-derived or recombinant C1-esterase inhibitors, icatibant, or ecallantide, alongside long-term prophylactic therapies to prevent swelling episodes.

Treatment for Hereditary Angioedema is highly individualized, as the frequency and severity of attacks vary significantly between patients. Clinical management is generally divided into three categories: on-demand therapy for acute attacks, short-term prophylaxis before medical procedures, and long-term prophylaxis to reduce disease burden.

Recommended Pharmacological Treatments

First-line therapies for Hereditary Angioedema include:

• C1-esterase inhibitors: These replace the missing or dysfunctional protein. Examples include C1-esterase inhibitor [human] (Cinryze, Berinert) and recombinant C1-esterase inhibitor (Ruconest).


• Bradykinin receptor antagonists: Icatibant (Firazyr) is a self-administered subcutaneous injection used to treat acute attacks.


• Plasma kallikrein inhibitors: Ecallantide (Kalbitor) is used to inhibit the pathway that triggers swelling.


• Long-term prophylaxis: Newer options like lanadelumab (Takhzyro) or oral berotralstat (Orladeyo) are often used to provide sustained prevention of Hereditary Angioedema attacks.

Multidisciplinary Care and Management

There is no surgical cure for Hereditary Angioedema, and non-pharmacological interventions are limited to avoiding known triggers, such as physical trauma or specific medications like ACE inhibitors. Because this condition impacts the circulatory and digestive systems, a multidisciplinary team is essential. Your care team should ideally include an allergist or immunologist, as well as access to an emergency department familiar with Hereditary Angioedema protocols. Clinical trials are currently investigating gene-editing therapies, which offer hope for potential future curative approaches.

Disclaimer: This information is for educational purposes only and does not constitute medical advice. All treatment plans, including the selection of medications and dosing, must be determined by your personal physician based on your specific clinical history and needs.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: The portal for rare diseases and orphan drugs


• Hereditary Angioedema Association (HAEA)